Hepatitis C virus: Difference between revisions
From IDWiki
(→) |
(→: added info about serology in Ontario) |
||
(18 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | == |
+ | ==Background== |
+ | ===Microbiology=== |
||
− | * Enveloped single-stranded RNA virus |
||
− | * NS5A and NS5B |
||
+ | *Enveloped single-stranded RNA virus in the genus ''Hepacivirus'' and family ''[[Flaviviridae]]'' |
||
− | == Life Cycle == |
||
+ | *NS5A and NS5B are important non-structural proteins |
||
+ | ===Life Cycle=== |
||
− | * NS5A…... |
||
− | * NS5B |
||
+ | *Involves protease, polymerase, and non-structural proteins (NS5A/NS5B) |
||
− | == Epidemiology == |
||
+ | ===Epidemiology=== |
||
− | * Worldwide about 70 million cases |
||
− | * '''Genotype''' varies by geography |
||
− | ** Genotype 1 most common worldwide |
||
− | ** Genotype 1a and 1b common in Canada |
||
− | *** Disproportionate burden in Indigienous Canadian population in the North |
||
− | *** Very high burden of disease in Canada, causing more years of life lost in Ontario than any other infectious disease |
||
− | ** Genotype 3 more common south-east Asia and in injection drug use |
||
− | ** Genotype 4 common in Egypt (15% prevalence); Egypt has the highest burden in the world |
||
− | * In '''Canada''', about 245,000 chronic hepatitis C, about half are undiagnosed |
||
− | ** Risk factors: injection drug use (highest risk), prior transfusion, and hemophilia |
||
− | ** Increasing burden of disease as patients age and progress to cirrhosis |
||
− | * Modes of transmission |
||
− | ** Injection drug use (most important population, highest risk) |
||
− | ** Tattoos |
||
− | ** Blood transfusions before 1992 |
||
− | ** Cocaine use from blood on the straws |
||
− | ** Rarely, sexual transmission especially HIV-infected MSM |
||
− | ** Vertical transmission rare (3-5%) |
||
− | ** Iatrogenic or medical transmission, from multi-use vials |
||
+ | *Worldwide about 70 million cases |
||
− | == Pathophysiology == |
||
+ | *'''Genotype''' varies by geography |
||
+ | **Genotype 1 most common worldwide |
||
+ | **Genotype 1a and 1b common in Canada |
||
+ | ***Disproportionate burden in Indigienous Canadian population in the North |
||
+ | ***Very high burden of disease in Canada, causing more years of life lost in Ontario than any other infectious disease |
||
+ | **Genotype 3 more common south-east Asia and in injection drug use |
||
+ | **Genotype 4 common in Egypt (15% prevalence); Egypt has the highest burden in the world |
||
+ | *In '''Canada''', about 245,000 chronic hepatitis C, about half are undiagnosed |
||
+ | **Risk factors: injection drug use (highest risk), prior transfusion, and hemophilia |
||
+ | **Increasing burden of disease as patients age and progress to cirrhosis |
||
+ | *Modes of transmission |
||
+ | **Injection drug use (most important population, highest risk) |
||
+ | **Tattoos |
||
+ | **Blood transfusions before 1992 |
||
+ | **Cocaine use from blood on the straws |
||
+ | **Rarely, sexual transmission especially HIV-infected MSM |
||
+ | **Vertical transmission rare (3-5%) |
||
+ | **Iatrogenic or medical transmission, from multi-use vials |
||
+ | ===Pathophysiology=== |
||
− | * In the acute phase, the viral load and liver enzymes fluctuate over months |
||
− | ** Anti-HCV-Ab develops at 12 weeks |
||
− | ** Acute phase lasts 6 months to 2 years |
||
− | * Spontaneous clearance is rare after 2 years |
||
− | ** Anti-HCV-Ab positive and HCV RNA negative |
||
− | ** Repeat to confirm, but no need to follow it |
||
− | ** No complications, though it is a surrogate for risk behaviours |
||
− | ** ''Not'' protected from reinfection |
||
− | * If it isn't cleared, it becomes chronic |
||
− | ** Lifetime risk of cirrhosis is 50-60%, with 20% having cirrhosis at 20 years |
||
− | ** Liver cancer develops in 1-4% |
||
+ | *In the acute phase, the viral load and liver enzymes fluctuate over months |
||
− | == Clinical Presentation == |
||
+ | **Anti-HCV-Ab develops at 12 weeks |
||
+ | **Acute phase lasts 6 months to 2 years |
||
+ | *Spontaneous clearance is rare after 2 years |
||
+ | **Anti-HCV-Ab positive and HCV RNA negative |
||
+ | **Repeat to confirm, but no need to follow it |
||
+ | **No complications, though it is a surrogate for risk behaviours |
||
+ | **''Not'' protected from reinfection |
||
+ | *If it isn't cleared, it becomes chronic |
||
+ | **Lifetime risk of cirrhosis is 50-60%, with 20% having cirrhosis at 20 years |
||
+ | **Liver cancer develops in 1-4% |
||
+ | ==Clinical Manifestations== |
||
− | * After exposure, may clear infection, but 70-80% become chronically infected |
||
− | * Progresses slowly and asymptomatically until they develop liver fibrosis, compensated cirrhosis, then decompensated cirrhosis |
||
− | ** ~20-25% progress to end-stage liver disease within 20 years |
||
+ | *After exposure, incubation period of [[Usual incubation period::5 to 12 weeks]] |
||
− | == Management == |
||
+ | *Not all have symptoms of primary infection, but if they do they are typically non-specific fatigue and myalgias, and occasionally jaundice |
||
+ | **Lasts 2 to 12 weeks |
||
+ | *About 25% have spontaneous viral clearance within 6 to 12 months, with the rest progressing to chronic infection |
||
+ | *Chronic infection progresses slowly and asymptomatically until they develop liver fibrosis, compensated cirrhosis, and finally decompensated cirrhosis |
||
+ | **~20-25% progress to end-stage liver disease within 20 years |
||
− | === |
+ | === Extrahepatic Manifestations === |
+ | * [[Vasculitis]] |
||
− | * All individuals should be considered for antiretroviral treatment |
||
+ | ** [[Mixed cryoglobulinemia]] |
||
− | * Assess readiness for treatment, as good adherence is necessary |
||
+ | ** [[Cryoglobulinemic vasculitis]] |
||
− | * Alcohol, drug use, and mental health disorders are ''not'' containdications to treatment |
||
+ | ** [[Sicca syndrome]] and [[Sjögren syndrome]] |
||
+ | ** [[Polyarteritis nodosa]] |
||
+ | * Hematologic disorders |
||
+ | ** [[B-cell lymphoma]] |
||
+ | ** [[Monoclonal gammopathies]] |
||
+ | ** [[Immune thrombocytopenia]] |
||
+ | ** [[Autoimmune hemolytic anemia]] |
||
+ | * Endocrine diseases |
||
+ | ** [[Type 2 diabetes mellitus]] |
||
+ | ** [[Hypothyroidism]] |
||
+ | * Renal disease |
||
+ | ** [[Membranoproliferative glomerulonephritis]] |
||
+ | ** [[Chronic kidney disease]] |
||
+ | * Dermatologic findings |
||
+ | ** [[Porphyria cutanea tarda]] |
||
+ | ** [[Lichen planus]] |
||
+ | ** [[Necrolytic acral erythema]] |
||
+ | ** [[Leukocytoclastic vasculitis]] |
||
+ | * Other |
||
+ | ** Arthralgias and myalgias are common |
||
+ | ** [[Cardiovascular disease]] |
||
+ | ** Neurologic disorders, including [[depression]], fatigue, and neurocognitive impairment, as well as [[neuropathy]] |
||
+ | * Autoantibodies, including [[rheumatoid factor]], [[ANA]], anticardiolipin antibody, anti-thyroid antibodies, and anti-smooth muscle antibody |
||
+ | ==Diagnosis== |
||
− | === Initial investigations === |
||
+ | *Screening with serology for anti-HCV antibodies followed by RNA PCR to confirm ongoing infection |
||
− | * Confirm active infection with HCV RNA then get genotype and subtype |
||
+ | **The window period for serology is about 5 to 10 weeks before antibodies are detectable |
||
− | ** Two positive HCV RNA tests 6 months apart documents chronic infection |
||
+ | **Viral RNA detectable 2 to 14 days after exposure |
||
− | ** May need resistance testing |
||
+ | *Anti-HCV antibodies appear to be lifelong but not protective against reinfection, so need to check RNA PCR to rule out reinfection |
||
− | * Baseline bloodwork, including CBC, liver enzymes, liver function, and creatinine |
||
+ | *In Ontario, serology is done with a two-tier algorithm (screening test and confirmatory test) |
||
− | * Serology to exclude HIV and HBV |
||
+ | **Screening test is chemiluminescent microparticle immunoassay (CMIA) |
||
− | * Transferrin saturation to exclude hemochromatosis, and IgG levels to exclude autimmune hepatitis |
||
+ | **Confirmatory test is a second chemiluminescence assay |
||
− | * Baseline liver ultrasound |
||
+ | **Interpretation: |
||
− | * If not clearly cirrhotic, assess liver fibrosis |
||
+ | ***Screening and confirmatory reactive: positive test |
||
− | ** Bloodwork: AST:platelet ratio index (APRI), FIB-4, FibroTest |
||
+ | ***Screening non-reactive: negative test |
||
− | ** Imaging: FibroScan |
||
+ | ***Screening reactive (or indeterminate) and confirmatory non-reactive (or indeterminate): inconclusive |
||
− | ** Gold standard: biopsy |
||
+ | ****Submit HCV RNA with repeat serology |
||
+ | ****If RNA not detected, repeat serology at 6-8 weeks |
||
+ | ****If repeatedly inconclusive, discuss with microbiologist |
||
− | == |
+ | ==Management== |
+ | ===Decision to Treat=== |
||
− | * Include nonstructural 3/4A (NS3/4A) serine protease (-previr), the NS5B RNA dependent RNA polymerase (-buvir) and the NS5A protein (-asvir) |
||
− | * Assess drug-drug interactions with [[https://www.hepdruginteractions.org/|www.hepdruginteractions.org]] |
||
− | ** PPI and Epclusa/Harvoni |
||
− | ** Statins require dose reduction; atorvastatin and Maviret is no-no |
||
− | ** Anti-epileptics except leviteracetam |
||
− | * Choice of treatment regimen depends on genotype, previously-failed treatments, and cirrhosis |
||
− | ** All protease inhibitors (-previr) are contraindicated in decompensated cirrhosis, which refers to ascites, esophageal variceal hemorrhage, jaundice, or hepatic encephalopathy |
||
− | ** Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is indicated for previously-treated patients |
||
+ | *All individuals should be considered for antiretroviral treatment |
||
+ | *Assess readiness for treatment, as good adherence is necessary |
||
+ | *Alcohol, drug use, and mental health disorders are ''not'' containdications to treatment |
||
+ | |||
+ | ===Initial Investigations=== |
||
+ | |||
+ | *Confirm active infection with HCV RNA then get genotype and subtype |
||
+ | **Two positive HCV RNA tests 6 months apart documents chronic infection, only needed in Ontario |
||
+ | **May need resistance testing |
||
+ | **Genotype only actually matters for cirrhosis (since we can otherwise pick a pan-genotypic regimen) |
||
+ | *Baseline bloodwork, including CBC, liver enzymes (ALT, AST, ALP), liver function (bilirubin, INR, albumin), and creatinine |
||
+ | *Serology to exclude HIV and HBV (HBsAg, anti-HBs, anti-HBc) |
||
+ | *Transferrin saturation to exclude [[hemochromatosis]] |
||
+ | *IgG levels, which if elevated can be suggestive of [[cirrhosis]] or possibly [[autoimmune hepatitis]] |
||
+ | *Baseline liver ultrasound |
||
+ | *If not clearly cirrhotic, assess liver fibrosis |
||
+ | **Bloodwork: [[AST:platelet ratio index]] (APRI), [[FIB-4]], FibroTest |
||
+ | **Imaging: FibroScan |
||
+ | **Gold standard: biopsy |
||
+ | |||
+ | ===Antivirals=== |
||
+ | |||
+ | *Include nonstructural 3/4A (NS3/4A) serine protease (-previr), the NS5B RNA dependent RNA polymerase (-buvir) and the NS5A protein (-asvir) |
||
+ | *Assess drug-drug interactions with [https://www.hepdruginteractions.org/ www.hepdruginteractions.org] |
||
+ | **PPIs interact with Epclusa and Harvoni |
||
+ | **Statins require dose reduction; avoid [[atorvastatin]] with Maviret |
||
+ | **Notable interactions with most anti-epileptics, except leviteracetam |
||
+ | **[[Sofosbuvir]] increases [[TDF]] levels |
||
+ | *Choice of treatment regimen depends on genotype, previously-failed treatments, and cirrhosis |
||
+ | **All protease inhibitors (-previr) are contraindicated in decompensated cirrhosis, which refers to ascites, esophageal variceal hemorrhage, jaundice, or hepatic encephalopathy |
||
+ | **[[Sofosbuvir]]/[[velpatasvir]]/[[voxilaprevir]] (Vosevi) is indicated for previously-treated patients |
||
+ | *Durations are typically between 8 and 12 weeks |
||
+ | **Epclusa 12 weeks for most, now covered by ODB |
||
+ | **Zepatier 12 weeks for G1 and G4 |
||
+ | **Maviret 8 weeks for most; 12 weeks for cirrhosis |
||
+ | **Harvoni 8 weeks if uncomplicated |
||
+ | |||
+ | ====Treatment-Naive Patients Without Cirrhosis==== |
||
{| class="wikitable" |
{| class="wikitable" |
||
− | ! Regimen |
+ | ! rowspan="2" |Regimen |
+ | ! colspan="7" |Duration by Genotype (weeks) |
||
− | ! 1a |
||
+ | ! rowspan="2" |Notes |
||
− | ! 1b |
||
− | ! 2 |
||
− | ! 3 |
||
− | ! 4 |
||
− | ! 5 |
||
− | ! 6 |
||
|- |
|- |
||
+ | !1a |
||
− | | Ledipasvir/sofosbuvir (Harvoni) |
||
+ | !1b |
||
− | | 12 wk ± ribavirin |
||
+ | !2 |
||
− | | 12 wk |
||
+ | !3 |
||
− | | – |
||
+ | !4 |
||
− | | 12 wk + ribavirin |
||
+ | !5 |
||
− | | 12 wk |
||
+ | !6 |
||
− | | 12 wk |
||
− | | 12 wk |
||
|- |
|- |
||
+ | |[[Ledipasvir]]/[[sofosbuvir]] (Harvoni) |
||
− | | Elbasvir/grazoprevir (Zepatier) |
||
− | | |
+ | |12 ± RBV |
− | | |
+ | |12 |
+ | |— |
||
− | | – |
||
− | | |
+ | |12 + RBV |
− | | |
+ | |12 |
+ | |12 |
||
− | | – |
||
+ | |12 |
||
− | | – |
||
+ | | |
||
|- |
|- |
||
+ | |[[Elbasvir]]/[[grazoprevir]] (Zepatier) |
||
− | | Sofosbuvir/velpatasvir (Epclusa) |
||
− | | |
+ | |12-16 ± RBV |
− | | |
+ | |12 |
+ | |— |
||
− | | 12 wk |
||
− | | |
+ | |12 + SOF |
− | | |
+ | |12 |
+ | |— |
||
− | | 12 wk |
||
+ | |— |
||
− | | 12 wk |
||
+ | |rule out resistance first in G1a |
||
|- |
|- |
||
+ | |[[Paritaprevir]]/[[ritonavir]]/[[ombitasvir]] + [[dasabuvir]] (Holkira Pak) |
||
− | | Glecaprevir/pibrentasvir (Maviret) |
||
− | | |
+ | |12 + RBV |
+ | |12 |
||
− | | 8 wk |
||
+ | |— |
||
− | | 8 wk |
||
+ | |— |
||
− | | 8 wk |
||
+ | |— |
||
− | | 8 wk |
||
+ | |— |
||
− | | 8 wk |
||
+ | |— |
||
− | | 8 wk |
||
+ | |add ribavirin for G1a |
||
|- |
|- |
||
+ | |[[Paritaprevir]]/[[ritonavir]]/[[ombitasvir]] (Technivie) |
||
− | | ... |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |12 + RBV |
||
+ | |— |
||
+ | |— |
||
| |
| |
||
+ | |- |
||
+ | |[[Sofosbuvir]] + [[daclatasvir]] |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
| |
| |
||
+ | |- |
||
+ | |[[Sofosbuvir]]/[[velpatasvir]] (Epclusa) |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
| |
| |
||
+ | |- |
||
+ | |[[Glecaprevir]]/[[pibrentasvir]] (Maviret) |
||
+ | |8 |
||
+ | |8 |
||
+ | |8 |
||
+ | |8 |
||
+ | |8 |
||
+ | |8 |
||
+ | |8 |
||
| |
| |
||
+ | |- |
||
+ | |[[Sofosbuvir]]/[[velpatasvir]]/[[voxilaprevir]] (Vosevi) |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |for treatment failure |
||
+ | |} |
||
+ | |||
+ | ====Treatment-Naive Patients With Cirrhosis==== |
||
+ | {| class="wikitable" |
||
+ | ! rowspan="2" |Regimen |
||
+ | ! colspan="7" |Duration by Genotype (weeks) |
||
+ | ! rowspan="2" |Notes |
||
+ | |- |
||
+ | !1a |
||
+ | !1b |
||
+ | !2 |
||
+ | !3 |
||
+ | !4 |
||
+ | !5 |
||
+ | !6 |
||
+ | |- |
||
+ | |[[Ledipasvir]]/[[sofosbuvir]] (Harvoni) |
||
+ | |12 ± RBV |
||
+ | |12 |
||
+ | |— |
||
+ | |12 + RBV |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
| |
| |
||
+ | |- |
||
+ | |[[Elbasvir]]/[[grazoprevir]] (Zepatier) |
||
+ | |12-16 ± RBV |
||
+ | |12 |
||
+ | |— |
||
+ | |12 + SOF |
||
+ | |12 |
||
+ | |— |
||
+ | |— |
||
+ | |rule out resistance first in G1a |
||
+ | |- |
||
+ | |[[Paritaprevir]]/[[ritonavir]]/[[ombitasvir]] + [[dasabuvir]] (Holkira Pak) |
||
+ | |12 + RBV |
||
+ | |12 |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |add ribavirin for G1a |
||
+ | |- |
||
+ | |[[Paritaprevir]]/[[ritonavir]]/[[ombitasvir]] (Technivie) |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |12 + RBV |
||
+ | |— |
||
+ | |— |
||
| |
| |
||
+ | |- |
||
+ | |[[Sofosbuvir]] + [[daclatasvir]] |
||
+ | |24 |
||
+ | |24 |
||
+ | |24 |
||
+ | |24 ± RBV |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
| |
| |
||
+ | |- |
||
+ | |[[Sofosbuvir]]/[[velpatasvir]] (Epclusa) |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 ± RBV |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | | |
||
+ | |- |
||
+ | |[[Glecaprevir]]/[[pibrentasvir]] (Maviret) |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | |12 |
||
+ | | |
||
+ | |- |
||
+ | |[[Sofosbuvir]]/[[velpatasvir]]/[[voxilaprevir]] (Vosevi) |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |— |
||
+ | |for treatment failure |
||
|} |
|} |
||
+ | ====Treatment-Experienced Patients==== |
||
− | * Epclusa 12 weeks for most, now OCB covered |
||
− | * Zepatier 12 weeks for G1 and G4 |
||
− | * Maviret 8 weeks for most; 12 weeks for cirrhosis |
||
− | * Harvoni 8 weeks if uncomplicated |
||
− | |||
− | === Experienced patients === |
||
− | * |
+ | *Changes the options, mostly longer courses of treatment |
− | === |
+ | ===Non-Pharmacologic Management=== |
− | * |
+ | *Counsel to avoid sharing products like needles or razors, safe sex, avoid alcohol |
− | * |
+ | *Vaccinate for [[hepatitis A]] and [[Hepatitis B virus|B]] |
− | === |
+ | ===Follow-Up=== |
− | * |
+ | *Need to confirm sustained virologic response (SVR), defined as negative PCR 12 weeks after completing therapy |
+ | *If they have achieved SVR |
||
+ | **In patients without cirrhosis, no specific follow-up is necessary |
||
+ | **In patients with cirrhosis, they should have biannual HCC screening with ultrasound |
||
+ | **Annual HCV RNA in patients with ongoing risk factors |
||
+ | *If they have not achieved, then they should be evaluated for salvage therapy |
||
− | == |
+ | ==Screening== |
− | * |
+ | *Majority of cases of chronic hepatitis C occur in baby boomers (born 1945 to 1975), though screening for this population appears to be controversial |
− | === |
+ | ===Populations to Screen=== |
− | * |
+ | *'''History of injection drug use, ever''' |
− | * |
+ | *History of incarceration |
− | * |
+ | *Received healthcare where there is a lack of IPAC |
− | * |
+ | *Blood products or organ transplantation before 1992 in Canada |
− | * |
+ | *Born or resided in a country where prevalence of HCV is >3% |
− | ** |
+ | **Central, East and South Asia |
− | ** |
+ | **Australasia and Oceania |
− | ** |
+ | **Eastern Europe |
− | ** |
+ | **Subsaharan Africa |
− | ** |
+ | **North Africa or the Middle East |
− | * |
+ | *Born to HCV positive mother |
− | * |
+ | *History of sharing personal care items or sex with an HCV-positive person |
− | * |
+ | *HIV infection |
− | * |
+ | *Received hemodialysis |
− | * |
+ | *Elevated ALT |
− | * |
+ | *'''Born between 1945 and 1975''' (baby boomers) |
− | ** |
+ | **Recommended in the US and by CASL but not by CTFPHC |
− | ==== |
+ | ====Opportunistic Screening==== |
− | * |
+ | *Emergency rooms |
− | * |
+ | *Hospital inpatients |
− | * |
+ | *Substance use treatment clinics |
− | === |
+ | ===Screening Procedure=== |
− | * |
+ | *Anti-HCV antibody |
+ | **Serum serology gold standard |
||
− | * If positive, proceed to HCV RNA |
||
+ | **There are some quick point-of-care tests, like from saliva |
||
− | * Should be done annually in patients who have ongoing high-risk exposures |
||
+ | **Also cheap options like dried blood spot testing, which can have RNA testing as well |
||
+ | *If positive, proceed to HCV RNA |
||
+ | **May be able to do it as reflex testing |
||
+ | *Should be done annually in patients who have ongoing high-risk exposures |
||
− | == |
+ | ==Further Reading== |
− | * |
+ | *Shah H, ''et al''. [https://doi.org/10.1503/cmaj.170453 The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver]. ''CMAJ''. 2018;190(22):E677-E687. |
− | * |
+ | *[https://doi.org/10.1093/cid/ciy585 Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection]. ''Clin Infect Dis''. 2018;67(10):1477-92. |
[[Category:Flaviviridae]] |
[[Category:Flaviviridae]] |
Latest revision as of 09:36, 15 September 2022
Background
Microbiology
- Enveloped single-stranded RNA virus in the genus Hepacivirus and family Flaviviridae
- NS5A and NS5B are important non-structural proteins
Life Cycle
- Involves protease, polymerase, and non-structural proteins (NS5A/NS5B)
Epidemiology
- Worldwide about 70 million cases
- Genotype varies by geography
- Genotype 1 most common worldwide
- Genotype 1a and 1b common in Canada
- Disproportionate burden in Indigienous Canadian population in the North
- Very high burden of disease in Canada, causing more years of life lost in Ontario than any other infectious disease
- Genotype 3 more common south-east Asia and in injection drug use
- Genotype 4 common in Egypt (15% prevalence); Egypt has the highest burden in the world
- In Canada, about 245,000 chronic hepatitis C, about half are undiagnosed
- Risk factors: injection drug use (highest risk), prior transfusion, and hemophilia
- Increasing burden of disease as patients age and progress to cirrhosis
- Modes of transmission
- Injection drug use (most important population, highest risk)
- Tattoos
- Blood transfusions before 1992
- Cocaine use from blood on the straws
- Rarely, sexual transmission especially HIV-infected MSM
- Vertical transmission rare (3-5%)
- Iatrogenic or medical transmission, from multi-use vials
Pathophysiology
- In the acute phase, the viral load and liver enzymes fluctuate over months
- Anti-HCV-Ab develops at 12 weeks
- Acute phase lasts 6 months to 2 years
- Spontaneous clearance is rare after 2 years
- Anti-HCV-Ab positive and HCV RNA negative
- Repeat to confirm, but no need to follow it
- No complications, though it is a surrogate for risk behaviours
- Not protected from reinfection
- If it isn't cleared, it becomes chronic
- Lifetime risk of cirrhosis is 50-60%, with 20% having cirrhosis at 20 years
- Liver cancer develops in 1-4%
Clinical Manifestations
- After exposure, incubation period of 5 to 12 weeks
- Not all have symptoms of primary infection, but if they do they are typically non-specific fatigue and myalgias, and occasionally jaundice
- Lasts 2 to 12 weeks
- About 25% have spontaneous viral clearance within 6 to 12 months, with the rest progressing to chronic infection
- Chronic infection progresses slowly and asymptomatically until they develop liver fibrosis, compensated cirrhosis, and finally decompensated cirrhosis
- ~20-25% progress to end-stage liver disease within 20 years
Extrahepatic Manifestations
- Vasculitis
- Hematologic disorders
- Endocrine diseases
- Renal disease
- Dermatologic findings
- Other
- Arthralgias and myalgias are common
- Cardiovascular disease
- Neurologic disorders, including depression, fatigue, and neurocognitive impairment, as well as neuropathy
- Autoantibodies, including rheumatoid factor, ANA, anticardiolipin antibody, anti-thyroid antibodies, and anti-smooth muscle antibody
Diagnosis
- Screening with serology for anti-HCV antibodies followed by RNA PCR to confirm ongoing infection
- The window period for serology is about 5 to 10 weeks before antibodies are detectable
- Viral RNA detectable 2 to 14 days after exposure
- Anti-HCV antibodies appear to be lifelong but not protective against reinfection, so need to check RNA PCR to rule out reinfection
- In Ontario, serology is done with a two-tier algorithm (screening test and confirmatory test)
- Screening test is chemiluminescent microparticle immunoassay (CMIA)
- Confirmatory test is a second chemiluminescence assay
- Interpretation:
- Screening and confirmatory reactive: positive test
- Screening non-reactive: negative test
- Screening reactive (or indeterminate) and confirmatory non-reactive (or indeterminate): inconclusive
- Submit HCV RNA with repeat serology
- If RNA not detected, repeat serology at 6-8 weeks
- If repeatedly inconclusive, discuss with microbiologist
Management
Decision to Treat
- All individuals should be considered for antiretroviral treatment
- Assess readiness for treatment, as good adherence is necessary
- Alcohol, drug use, and mental health disorders are not containdications to treatment
Initial Investigations
- Confirm active infection with HCV RNA then get genotype and subtype
- Two positive HCV RNA tests 6 months apart documents chronic infection, only needed in Ontario
- May need resistance testing
- Genotype only actually matters for cirrhosis (since we can otherwise pick a pan-genotypic regimen)
- Baseline bloodwork, including CBC, liver enzymes (ALT, AST, ALP), liver function (bilirubin, INR, albumin), and creatinine
- Serology to exclude HIV and HBV (HBsAg, anti-HBs, anti-HBc)
- Transferrin saturation to exclude hemochromatosis
- IgG levels, which if elevated can be suggestive of cirrhosis or possibly autoimmune hepatitis
- Baseline liver ultrasound
- If not clearly cirrhotic, assess liver fibrosis
- Bloodwork: AST:platelet ratio index (APRI), FIB-4, FibroTest
- Imaging: FibroScan
- Gold standard: biopsy
Antivirals
- Include nonstructural 3/4A (NS3/4A) serine protease (-previr), the NS5B RNA dependent RNA polymerase (-buvir) and the NS5A protein (-asvir)
- Assess drug-drug interactions with www.hepdruginteractions.org
- PPIs interact with Epclusa and Harvoni
- Statins require dose reduction; avoid atorvastatin with Maviret
- Notable interactions with most anti-epileptics, except leviteracetam
- Sofosbuvir increases TDF levels
- Choice of treatment regimen depends on genotype, previously-failed treatments, and cirrhosis
- All protease inhibitors (-previr) are contraindicated in decompensated cirrhosis, which refers to ascites, esophageal variceal hemorrhage, jaundice, or hepatic encephalopathy
- Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is indicated for previously-treated patients
- Durations are typically between 8 and 12 weeks
- Epclusa 12 weeks for most, now covered by ODB
- Zepatier 12 weeks for G1 and G4
- Maviret 8 weeks for most; 12 weeks for cirrhosis
- Harvoni 8 weeks if uncomplicated
Treatment-Naive Patients Without Cirrhosis
Regimen | Duration by Genotype (weeks) | Notes | ||||||
---|---|---|---|---|---|---|---|---|
1a | 1b | 2 | 3 | 4 | 5 | 6 | ||
Ledipasvir/sofosbuvir (Harvoni) | 12 ± RBV | 12 | — | 12 + RBV | 12 | 12 | 12 | |
Elbasvir/grazoprevir (Zepatier) | 12-16 ± RBV | 12 | — | 12 + SOF | 12 | — | — | rule out resistance first in G1a |
Paritaprevir/ritonavir/ombitasvir + dasabuvir (Holkira Pak) | 12 + RBV | 12 | — | — | — | — | — | add ribavirin for G1a |
Paritaprevir/ritonavir/ombitasvir (Technivie) | — | — | — | — | 12 + RBV | — | — | |
Sofosbuvir + daclatasvir | 12 | 12 | 12 | 12 | — | — | — | |
Sofosbuvir/velpatasvir (Epclusa) | 12 | 12 | 12 | 12 | 12 | 12 | 12 | |
Glecaprevir/pibrentasvir (Maviret) | 8 | 8 | 8 | 8 | 8 | 8 | 8 | |
Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) | — | — | — | — | — | — | — | for treatment failure |
Treatment-Naive Patients With Cirrhosis
Regimen | Duration by Genotype (weeks) | Notes | ||||||
---|---|---|---|---|---|---|---|---|
1a | 1b | 2 | 3 | 4 | 5 | 6 | ||
Ledipasvir/sofosbuvir (Harvoni) | 12 ± RBV | 12 | — | 12 + RBV | 12 | 12 | 12 | |
Elbasvir/grazoprevir (Zepatier) | 12-16 ± RBV | 12 | — | 12 + SOF | 12 | — | — | rule out resistance first in G1a |
Paritaprevir/ritonavir/ombitasvir + dasabuvir (Holkira Pak) | 12 + RBV | 12 | — | — | — | — | — | add ribavirin for G1a |
Paritaprevir/ritonavir/ombitasvir (Technivie) | — | — | — | — | 12 + RBV | — | — | |
Sofosbuvir + daclatasvir | 24 | 24 | 24 | 24 ± RBV | — | — | — | |
Sofosbuvir/velpatasvir (Epclusa) | 12 | 12 | 12 | 12 ± RBV | 12 | 12 | 12 | |
Glecaprevir/pibrentasvir (Maviret) | 12 | 12 | 12 | 12 | 12 | 12 | 12 | |
Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) | — | — | — | — | — | — | — | for treatment failure |
Treatment-Experienced Patients
- Changes the options, mostly longer courses of treatment
Non-Pharmacologic Management
- Counsel to avoid sharing products like needles or razors, safe sex, avoid alcohol
- Vaccinate for hepatitis A and B
Follow-Up
- Need to confirm sustained virologic response (SVR), defined as negative PCR 12 weeks after completing therapy
- If they have achieved SVR
- In patients without cirrhosis, no specific follow-up is necessary
- In patients with cirrhosis, they should have biannual HCC screening with ultrasound
- Annual HCV RNA in patients with ongoing risk factors
- If they have not achieved, then they should be evaluated for salvage therapy
Screening
- Majority of cases of chronic hepatitis C occur in baby boomers (born 1945 to 1975), though screening for this population appears to be controversial
Populations to Screen
- History of injection drug use, ever
- History of incarceration
- Received healthcare where there is a lack of IPAC
- Blood products or organ transplantation before 1992 in Canada
- Born or resided in a country where prevalence of HCV is >3%
- Central, East and South Asia
- Australasia and Oceania
- Eastern Europe
- Subsaharan Africa
- North Africa or the Middle East
- Born to HCV positive mother
- History of sharing personal care items or sex with an HCV-positive person
- HIV infection
- Received hemodialysis
- Elevated ALT
- Born between 1945 and 1975 (baby boomers)
- Recommended in the US and by CASL but not by CTFPHC
Opportunistic Screening
- Emergency rooms
- Hospital inpatients
- Substance use treatment clinics
Screening Procedure
- Anti-HCV antibody
- Serum serology gold standard
- There are some quick point-of-care tests, like from saliva
- Also cheap options like dried blood spot testing, which can have RNA testing as well
- If positive, proceed to HCV RNA
- May be able to do it as reflex testing
- Should be done annually in patients who have ongoing high-risk exposures
Further Reading
- Shah H, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677-E687.
- Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2018;67(10):1477-92.